Kenneth Osiezagha, MD
Psychiatry · Lake Jackson, TXNPI 1205181724
Payments from drug & device makers
Across 616 payments — averaging $25.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Almatica Pharma LLC$7K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$873
- Lundbeck LLC$668
- Otsuka America Pharmaceutical, Inc.$660
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$6,46041%
- Food & beverage$8,89757%
- Education$2472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Almatica Pharma LLC | 43 | $6,879 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 116 | $1,691 |
| AbbVie(2 entities) | 106 | $1,338 |
| Takeda Pharmaceuticals U.S.A., Inc. | 51 | $873 |
| Lundbeck LLC | 38 | $668 |
| Otsuka America Pharmaceutical, Inc. | 46 | $660 |
| Teva Pharmaceuticals USA, Inc. | 25 | $547 |
| Supernus Pharmaceuticals, Inc. | 39 | $526 |
| Alkermes, Inc. | 29 | $438 |
| Corium, LLC | 21 | $335 |
| Sunovion Pharmaceuticals Inc. | 28 | $321 |
| Vanda Pharmaceuticals Inc. | 14 | $246 |
| Axsome Therapeutics, Inc. | 15 | $233 |
| Johnson & Johnson | 8 | $154 |
| Tris Pharma Inc | 8 | $148 |
| E.r. Squibb & Sons, L.L.C. | 5 | $99 |
| Eisai Inc. | 3 | $64 |
| Lilly USA, LLC | 3 | $63 |
| Indivior Inc. | 3 | $63 |
| Neurocrine Biosciences, Inc. | 4 | $59 |
| Tempus AI, Inc | 1 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Nevro Corp. | 1 | $22 |
| Brainsway USA Inc | 1 | $19 |
| Merck | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Neos Therapeutics, LP | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOREEV XR$6,460
How this compares
$15,604 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 134 | $230,451 |
| VraylarCariprazine Hcl | 31 | $53,175 |
| SpravatoEsketamine Hcl | 11 | $24,099 |
| TrintellixVortioxetine Hydrobromide | 11 | $12,462 |
| DayvigoLemborexant | 14 | $6,221 |
| Aripiprazole | 114 | $5,601 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 23 | $5,179 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $4,552 |
| Duloxetine Hcl | 199 | $3,820 |
| Bupropion XlBupropion Hcl | 173 | $3,011 |
| Clonazepam | 430 | $2,963 |
| Mirtazapine | 184 | $2,823 |
| Eszopiclone | 178 | $2,629 |
| Estazolam | 19 | $2,529 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 116 | $2,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $660 | $230,451134 claims |
| AbbVieVraylar | $1,338 | $53,17531 claims |
| Johnson & JohnsonSpravato | $154 | $24,09911 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $873 | $17,01524 claims |
| Eisai Inc.Dayvigo | $64 | $6,22114 claims |
| Lilly USA, LLCOlanzapine | $63 | $1,951135 claims |
| Almatica Pharma LLCSertraline Hcl | $6,879 | $1,217252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Lake Jackson
- Rakesh JainLake Jackson$7.2M
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.